News
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal $1.3 billion, The WSJ reported.
Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...
Investigators conducted polygraph interviews as part of the effort to determine what happened to Lilly and Jack Sullivan.
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback